Can you recommend recent obesity studies for a journal club that cover topics not previously presented by a colleague?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Recent Obesity Topics for Journal Club

For a fresh journal club presentation, I strongly recommend focusing on the 2025 WHO guideline on GLP-1 therapies for obesity 1 or the emerging diagnostic frameworks that move beyond BMI 2, as these represent paradigm shifts in how we conceptualize and treat obesity.

Novel Topics Worth Presenting

1. WHO GLP-1 Therapy Guidelines (2025)

The WHO issued its first-ever guideline specifically addressing GLP-1 therapies for obesity management 1. This is groundbreaking because:

  • Key recommendation: Long-term GLP-1 therapies combined with intensive behavioral therapy (conditional recommendation)
  • Recognizes obesity as a chronic, relapsing disease requiring lifelong care
  • Addresses critical implementation challenges: equitable access, cost, system readiness, and the need for transparent frameworks to identify highest-need patients
  • Emphasizes that medication alone cannot solve obesity—requires building integrated obesity ecosystems
  • This represents a global health policy shift, not just clinical guidance

2. New Diagnostic Frameworks Beyond BMI (2026)

Multiple major societies (EASO, Lancet Commission, ACC, AACE) have advanced new diagnostic approaches that fundamentally change how we define obesity 2:

  • Paradigm shift: Diagnosis now based on excess adiposity PLUS evidence of organ dysfunction or functional impairment
  • Moves away from BMI-only diagnosis toward multimodal assessment
  • Integrates anthropometric precision with standardized complication assessment
  • Supports earlier risk identification and more equitable, patient-centered care
  • The clinical implementation of these frameworks remains an active area of debate

3. 2025 VA/DoD Updated Guidelines (2026)

Fresh off the press with several practice-changing recommendations 3:

  • No requirement to complete lifestyle intervention before initiating pharmacotherapy—this challenges traditional stepped-care approaches
  • Flexible, individualized integration of medications and lifestyle interventions
  • Strong recommendation against discontinuing effective medications (prevents weight regain)
  • Waist circumference plus BMI for refined risk assessment (≥23 kg/m² threshold for Asian adults)
  • Stigma-informed care explicitly incorporated

4. Precision Medicine and Multi-Target Therapies (2025)

Emerging personalized approaches 4:

  • Gut microbiome research informing treatment selection
  • Multi-target therapies beyond single-mechanism drugs
  • Precision medicine approaches tailoring treatment to individual metabolic profiles
  • Less than 25% of patients currently receive evidence-based treatment—massive treatment gap

Why These Topics Stand Out

These are not rehashes of "obesity is multifactorial" or "use lifestyle interventions first." They represent:

  1. Policy-level changes (WHO guideline addressing global equity)
  2. Diagnostic revolution (moving beyond BMI after decades)
  3. Treatment sequencing changes (no mandatory lifestyle-first approach)
  4. Implementation science (how to actually deliver care equitably)

Common Pitfalls to Avoid

  • Don't present another general obesity management overview—colleagues have likely covered this
  • Avoid focusing solely on GLP-1 efficacy data (weight loss percentages)—everyone knows these drugs work
  • Skip basic epidemiology unless connecting to novel equity frameworks
  • Don't ignore the implementation challenges—these guidelines explicitly address feasibility, cost, and access

The most compelling presentation would compare the 2025 WHO guideline 1 with the 2026 VA/DoD guideline 3 to highlight how different health systems are operationalizing similar evidence with different constraints and priorities.

References

Related Questions

In an obese patient with a cervical collar undergoing cervical spine surgery, which site is preferred for central venous catheter placement?
Which laboratory tests should be ordered for a 7-year-old child with obesity?
What would be the estimated weight of a 10-year-old child with a BMI of 35.9 kg/m²?
Does a 7-year-old child who has gained 10 lb over the past year meet criteria for obesity?
What ASA physical status classification should be assigned to a patient with obesity based on BMI and any associated comorbidities?
What is the appropriate amiodarone dosing regimen for rapid control of a fast ventricular rate?
Are metformin and telmisartan safe for use during pregnancy?
What glucagon dose and repeat dosing schedule should be used for severe hypoglycemia, including route and considerations for sulfonylurea therapy?
What is the safest pharmacologic alternative to metformin for a pregnant woman with gestational diabetes or type 2 diabetes?
How does methadone compare to hydromorphone (Dilaudid) in analgesic potency?
Is rectal bleeding that occurs only with flatulence more likely caused by hemorrhoids?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.